Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future
Abstract Myasthenia gravis (MG) is a rare autoimmune disease that causes debilitating muscle weakness due to impaired neuromuscular transmission. Since most (about 80–90%) MG patients present autoantibodies against the acetylcholine receptor, standard medical therapy consists of symptomatic treatment with acetylcholinesterase inhibitors (e.g., pyridostigmine). In addition, considering the autoimmune basis of MG, standard therapy includes immunomodulating agents, such as corticosteroids, azathioprine, cyclosporine A, and cyclophosphamide. New strategies have been proposed for the treatment of MG and include complement blockade (i.e., eculizumab, ravulizumab, and zilucoplan) and neonatal Fc receptor antagonism (i.e., efgartigimod and rozanolixizumab). The aim of this review is to provide a detailed overview of the pre- and post-marketing evidence on the five pharmacological treatments most recently approved for the treatment of MG, by identifying both preclinical and clinical studies registered in clinicaltrials.gov. A description of the molecules currently under evaluation for the treatment of MG is also provided..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
CNS drugs - 38(2024), 1 vom: Jan., Seite 15-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crisafulli, Salvatore [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s40263-023-01059-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05452959X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05452959X | ||
| 003 | DE-627 | ||
| 005 | 20240126064714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40263-023-01059-8 |2 doi | |
| 035 | |a (DE-627)SPR05452959X | ||
| 035 | |a (SPR)s40263-023-01059-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crisafulli, Salvatore |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Myasthenia gravis (MG) is a rare autoimmune disease that causes debilitating muscle weakness due to impaired neuromuscular transmission. Since most (about 80–90%) MG patients present autoantibodies against the acetylcholine receptor, standard medical therapy consists of symptomatic treatment with acetylcholinesterase inhibitors (e.g., pyridostigmine). In addition, considering the autoimmune basis of MG, standard therapy includes immunomodulating agents, such as corticosteroids, azathioprine, cyclosporine A, and cyclophosphamide. New strategies have been proposed for the treatment of MG and include complement blockade (i.e., eculizumab, ravulizumab, and zilucoplan) and neonatal Fc receptor antagonism (i.e., efgartigimod and rozanolixizumab). The aim of this review is to provide a detailed overview of the pre- and post-marketing evidence on the five pharmacological treatments most recently approved for the treatment of MG, by identifying both preclinical and clinical studies registered in clinicaltrials.gov. A description of the molecules currently under evaluation for the treatment of MG is also provided. | ||
| 700 | 1 | |a Boccanegra, Brigida |4 aut | |
| 700 | 1 | |a Carollo, Massimo |4 aut | |
| 700 | 1 | |a Bottani, Emanuela |4 aut | |
| 700 | 1 | |a Mantuano, Paola |4 aut | |
| 700 | 1 | |a Trifirò, Gianluca |0 (orcid)0000-0003-1147-7296 |4 aut | |
| 700 | 1 | |a De Luca, Annamaria |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS drugs |d Berlin [u.a.] : Springer, 1994 |g 38(2024), 1 vom: Jan., Seite 15-32 |w (DE-627)SPR03306525X |w (DE-600)2043806-0 |x 1179-1934 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:1 |g month:01 |g pages:15-32 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40263-023-01059-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 1 |c 01 |h 15-32 | ||